Stand Up To Cancer and SandboxAQ announced a collaboration that brings SandboxAQ’s Large Quantitative Models to SU2C-funded cancer research projects.
Leaders of three health agencies presented new initiatives focused on patient-centered research, diversity in clinical trial enrollment, and innovation in clinical research.
While cutting-edge therapies grace headlines, the impact of breakthrough research remains limited due to patient access, affordability, and adherence.
U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.
In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.
Feb. 16, 2024, is a landmark date in the history of immuno-oncology.
As a student at MIT in the 1970s, Roderic Pettigrew was writing his PhD thesis on how a controlled nuclear reaction in the brain, boron neutron activation therapy, could be used to treat glioblastoma multiforme.
